Navigation Links
Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
Date:2/12/2013

lopment and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  The sBLA for XIAFLEX for the treatment of Peyronie's disease was submitted to the FDA in November 2012.  Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy).  Auxilium also has rights to pursue additional indications for CCH. For additional information, visit http://www.auxilium.com

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to Auxilium's strategy, progress and timing of development programs and related trials, the efficacy of its product candidates, the commercial benefits available to it as a result of its agreements with third parties, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
9. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
10. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Oven Industries Inc. announces a new ... 5R6-900 benchtop controller has many outstanding user-friendly benefits. Contained ... into the wall as a self-contained temperature control system, ... makes the device unique, as well as highly convenient ... can also be used universally, which allows the user ...
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific Shore ... based products across a broad range of product ... retained investor relations firm, BlueWater Advisory Group, to ... to trading process, and to direct the company,s ... Matthew Mills , ...
(Date:5/20/2013)... With bed bugs' presence come problems in various terms. ... to be eliminated, one must make sure that the bed ... so to help bed bug sufferers get that done, it ... bugs without using harmful pesticides. In it, the company ... Bug Bully. , According to My Cleaning Products, contrary to ...
(Date:5/20/2013)... 2013   Flexion Therapeutics , Inc. today announced ... to its management team as chief financial officer. ... management experience with biotechnology and medical device companies. ... financial officer for Novavax (NASDAQ: NVAX ) ... $250 million through a combination of investment funding and ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Pacific Shore Holdings Retains Investor Relations Firm 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2
... Incorporated,(Nasdaq: GPRO ) announced today that the Company ... on Tuesday, September 9,2008 at approximately 2:45 p.m. Eastern ... may be accessed through a link on the investors,section ... be available for 30 days following the event., ...
... during industry-leading event September 10 - 11, ... 2008 ... Plexus Systems, Inc.,provider of Plexus Online on-demand software for the ... 10-11, 2008 at the San Jose McEnery Conference Center, San ...
... The 33rd ESMO Congress,in Stockholm, the premier European ... medical oncologists, as well as a focal point ... The Congress Centre will be the venue for ... discuss critical issues for,European oncology such as cancer ...
Cached Biology Technology:Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference 2Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference 233rd ESMO Congress in Stockholm, 12-16 September 2008 233rd ESMO Congress in Stockholm, 12-16 September 2008 333rd ESMO Congress in Stockholm, 12-16 September 2008 433rd ESMO Congress in Stockholm, 12-16 September 2008 5
(Date:5/20/2013)... - A National Science Foundation (NSF) planning grant will ... (CARD), a joint program of the University of Illinois ... Mass. , "CARD will be devoted to research in ... agricultural products; forestry and paper products; chemical products; textiles; ... professor of food science and human nutrition and the ...
(Date:5/19/2013)... A novel study reports that white men and women ... bunions (hallux valgus) and lesser toe deformities, including hammer ... first to estimate the heritability of foot disorders in ... journal published by Wiley on behalf of the American ... that as many as 60% of older adults have ...
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) explores ... the impact of coffee on autoimmune disease and palliative ... recently has been associated with reduced risk of fibrosis, ... cups of java each month also correlate with lower ... the Mayo Clinic, Rochester, MN, linked coffee consumption with ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Blame your parents for bunion woes 2Coffee consumption associated with reduced risk of autoimmune liver disease 2
... blood clot-dissolving medication that is administered to some patients ... reduce the risk of amputation following severe frostbite, according ... of Surgery, one of the JAMA/Archives journals. , Frostbite ... 25 years, according to background information in the article. ...
... the University of Central Florida is proving promising as ... disease that can cause blindness and affects millions of ... the blood-brain barrier making it an effective non-toxic tool ... with appointments in UCF’s Advanced Materials Processing and Analysis ...
... A major obstacle in the treatment of infections and ... which prevents systemically delivered therapeutic drugs from reaching the ... Infectious Diseases, part of the National Institutes of Health, ... the rabies virus can carry a strip of therapeutic ...
Cached Biology News:Clot-dissolving agent may be beneficial in treatment of severe frostbite 2UCF nanoparticle offers promise for treating glaucoma 2Blood-brain barrier breached by new therapeutic strategy 2
Request Info...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
Anti Human JAM-1, Monoclonal Antibody, Clone M.Ab.F11...
Biology Products: